Albert Einstein College of Medicine

CytoDyn Inc. (CYDY) reports significant 2024 progress, including FDA lifting leronlimab's clinical hold, submitting two trial protocols, settling with Amarex for $10 million, and initiating pre-clinical/clinical trials. Focus areas include oncology (colorectal cancer, triple-negative breast cancer, glioblastoma) and inflammation (HIV-related chronic inflammation, Alzheimer's Disease, chronic fatigue syndrome). The company believes it has sufficient cash to advance development into 2025.

Ubrelvy (ubrogepant) showed 73% more effectiveness in reducing migraine disability within 2 hours compared to placebo in a clinical trial, potentially improving quality of life for migraine sufferers.